NCT05789407

Brief Summary

The health toxicity of polycyclic aromatic hydrocarbons (PAHs), present in air and food, generated during energy production and waste incineration, is well known. PAHs can activate the aryl hydrocarbon receptor, which may interact with classic estrogen receptors and modify estrogen-dependent inflammation in endometriosis. There is no data on the hypothetical role of PAHs in the etiopathogenesis of endometriosis. The aim was to compare PAHs concentrations in visceral fat in women with endometriosis and idiopathic infertility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 5, 2023

Completed
24 days until next milestone

First Posted

Study publicly available on registry

March 29, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

12 months

First QC Date

March 5, 2023

Last Update Submit

November 16, 2023

Conditions

Keywords

Endometriosis, Unexplained Infertility, Polycyclic aromatic hydrocarbons

Outcome Measures

Primary Outcomes (2)

  • Accumulation and detection of PAHs in women's visceral fat.

    Detection and confirmation of the accumulation of PAHs (acenaphthene, acenaphthylene, anthracene, fluoranthene, fluorene, naphthalene, phenanthrene, pyrene, benz\[a\]anthracene, benzo\[b\]fluoranthene, benzo\[k\]fluoranthene, benzo\[ghi\]perylene, benzo\[a\]pyrene, chrysene, dibenz\[a,h\]anthracene, and indeno\[1,2,3-cd\]pyrene) in human adipose tissue by gas chromatography-isotope dilution mass spectrometry method.

    up to 6 months

  • Comparison of concentrations of 16 reference PAHs in women in both study arms.

    Comparison of concentrations of 16 PAHs (acenaphthene, acenaphthylene, anthracene, fluoranthene, fluorene, naphthalene, phenanthrene, pyrene, benz\[a\]anthracene, benzo\[b\]fluoranthene, benzo\[k\]fluoranthene, benzo\[ghi\]perylene, benzo\[a\]pyrene, chrysene, dibenz\[a,h\]anthracene, and indeno\[1,2,3-cd\]pyrene) in both study arms using standard statistical methods.

    up to 6 months

Secondary Outcomes (3)

  • Evaluation of PAHs concentrations correlation with endometriosis degree

    up to 6 months

  • Evaluation of PAHs concentrations correlation with the intensity of pelvic pain

    up to 6 months

  • Evaluation of PAHs concentrations correlation with the presence and severity of peritoneal adhesions

    up to 6 months

Study Arms (2)

endometriosis

EXPERIMENTAL

Women subjected to elective laparoscopy for pelvic endometriosis

Diagnostic Test: Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry

idiopathic infertility

ACTIVE COMPARATOR

Women subjected to elective laparoscopy for idiopathic infertility

Diagnostic Test: Detection of PAHs in visceral fat with gas chromatography-isotope dilution mass spectrometry

Interventions

1 ml sample of visceral fat collected during elective laparoscopy for detection of PAHS by gas chromatography-isotope dilution mass spectrometry

endometriosisidiopathic infertility

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • i) age 18-45, ii) indications for surgical treatment of endometriosis, iii) indications for invasive diagnostics and surgical treatment of idiopathic infertility.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jagiellonian University Medical College, Department of Gynecology and Obstetrics

Krakow, 31-501, Poland

Location

MeSH Terms

Conditions

Endometriosis

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Study Officials

  • Robert Jach, Prof.

    Jagiellonian University

    STUDY CHAIR
  • Iwona Gawron, Ph.D.

    Jagiellonian University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: A prospective cohort tertiary-center study among women undergoing elective laparoscopy due to pelvic endometriosis (arm 1) or idiopathic infertility (arm 2).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ph.D., Principal Investigator

Study Record Dates

First Submitted

March 5, 2023

First Posted

March 29, 2023

Study Start

July 1, 2022

Primary Completion

June 30, 2023

Study Completion

October 1, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Locations